Six local health innovators benefit from new Innovation Funds.
We are pleased to announce the successful companies and innovators in the first round of our new Innovation Funds.
Managed through the Innovation Nexus portal, the funds focus on different stages of the journey from product development to piloting and roll-out. The Innovation Nexus provides advice and support for innovators wanting to work with the NHS, and has helped over 250 companies since its inception in 2014. This first round of funds attracted applications from a wide range of disciplines, including mental health, cancer, kidney health and digital technology for health.
Dr Linda Magee, Executive Director of Industry & Wealth at GM AHSN said:
“The standard of applications was very high, with the dedication of the teams clear throughout the application process. We are pleased to be able to offer funding to support such a varied selection of partnership projects with the NHS and I wish all the innovators every success in their ongoing work.”
The winning companies and innovation partnerships were awarded between £15-£50K each.
- SensAm Ltd: developing a new test for bladder and prostate cancer
- SRFT, CMFT and TRUSTECH: aid for patient safety in colonoscopy
- Microbiosensor: identifying infection in home dialysis patients
- Affigo CIC, Clintouch: mobile technology to support people with psychosis
- Liquid Bronze Ltd. (trading as Malinko): scheduling software for improving community nursing
- U-drain Ltd: new approach to drainage for people on home dialysis
Gordon Barker, of Microbiosensor said:
“We're delighted to receive this Energise Fund award and extremely grateful to the GM AHSN team for their support. The award will be transformational for Microbiosensor, allowing us to perform the first clinical trial of our novel infection monitor, "PD Safe", with patients attending peritoneal dialysis clinics here in Greater Manchester. This will help validate our point-of-care diagnostic technology, pave the way for subsequent (larger) clinical studies and accelerate our progress to market.”
Ged Murphy of U-Drain said:
“Using the amount secured through GM AHSN's Momentum Fund, U-drain Ltd will trial its innovative urine/dialysate waste drainage system with our partners at Salford Royal NHS Foundation Trust Renal Unit, led by Dr David Lewis (Head Peritoneal Dialysis Consultant).
We hope to use results of this trial, once published, to demonstrate the patient, economic and environmental benefits of U-Drain to renal units across the UK."
James Corden representing SRFT, CMFT and TRUSTECH said:
“We have already proven the concept for our colonoscopy overtube using a very basic prototype that was tested in a colonoscopy simulator device. The AHSN Energise Funding will enable us to develop more sophisticated prototypes and to test them in more realistic simulators. We are hoping that the data gathered during this work will help us to secure the interest of a commercial partner to bring the device to market.”
Frank Kvasnik of SensAm Ltd. said:
“GM AHSN support, in addition to input from NHS staff, means that we will be able to design and carry out a proof of principle study of our new diagnostic test for bladder and prostate cancer with a minimum delay. A large part of the resources will be used to reimburse NHS for the staff time devoted to this study and some of the funding will also be used to modify and adapt our current hardware for the new application, since it was originally developed for diagnostic breath tests.”
Charlotte Stockton-Powdrell of ClinTouch said:
Applications for the Ignite Fund and the next round of the Momentum Fund will be launched at an event at the NOWGEN Centre, on November 8th. For more details please contact the Innovation Nexus team: email@example.com
“We are delighted to have been awarded this funding from GM AHSN. Our project will focus on rolling-out the ClinTouch app across more mental health teams in Greater Manchester so that we can extend our reach and help more people with serious mental illness (SMI) to better manage their symptoms. These funds will help with the integration of ClinTouch into existing clinical systems and the refining of our relapse alert so that we can continue to try and prevent costly and unpleasant readmissions to hospital for people with SMI.”